889 related articles for article (PubMed ID: 29910030)
21. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
22. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
23. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Cicero AFG; Fogacci F; Cincione I
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
[No Abstract] [Full Text] [Related]
24. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
[TBL] [Abstract][Full Text] [Related]
26. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
27. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
Thompson PD; MacDougall DE; Newton RS; Margulies JR; Hanselman JC; Orloff DG; McKenney JM; Ballantyne CM
J Clin Lipidol; 2016; 10(3):556-67. PubMed ID: 27206943
[TBL] [Abstract][Full Text] [Related]
28. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
29. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
30. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
31. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
Lekuona I; Pintó X
Clin Investig Arterioscler; 2021 May; 33 Suppl 1():58-64. PubMed ID: 33966815
[TBL] [Abstract][Full Text] [Related]
32. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
[TBL] [Abstract][Full Text] [Related]
33. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
34. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
[TBL] [Abstract][Full Text] [Related]
37. Real-world utilization of bempedoic acid in an academic preventive cardiology practice.
Warden BA; Cardiology BA; Purnell JQ; Duell PB; Fazio S
J Clin Lipidol; 2022; 16(1):94-103. PubMed ID: 34924351
[TBL] [Abstract][Full Text] [Related]
38. Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis.
Masson W; Lobo M; Lavalle-Cobo A; Molinero G
Clin Investig Arterioscler; 2021; 33(3):117-126. PubMed ID: 33328138
[TBL] [Abstract][Full Text] [Related]
39. Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Bhagavathula AS; Al Matrooshi NO; Clark CCT; Rahmani J
Clin Drug Investig; 2021 Jan; 41(1):19-28. PubMed ID: 33368025
[TBL] [Abstract][Full Text] [Related]
40. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.
Koba S; Inoue I; Cyrille M; Lu C; Inomata H; Shimauchi J; Kajinami K
J Atheroscler Thromb; 2020 May; 27(5):471-484. PubMed ID: 31748467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
